Annovis Bio Return on Equity

Annovis Bio (ANVS) currently reports a ROE of 316.61%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Annovis Bio's ROE history and peer comparisons.

Annovis Bio's ROE of 316.61% is higher than the Healthcare sector average of 13.1%. That is roughly 2316.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Annovis Bio's current 316.61% should be judged against Healthcare norms (sector average: 13.1%) and against ANVS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 316.61%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Annovis Bio, and consider following ANVS for alerts when major investors trade the stock.

Annovis Bio is classified in the Healthcare sector. On ROE, it currently shows 316.61% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ANVS with unrelated industries.